Patent classifications
A61P1/10
Low-Dose Stable Formulations of Linaclotide
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient
A pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same. A composition for preventing/ameliorating an adult disease such as metabolic syndrome, diabetes, hyperlipidemia, hypertension, impaired liver function, renal failure, adiposity, erectile dysfunction, menopausal disorder, shoulder discomfort, and low back pain, comprising 5-aminolevulinic acid (ALA), its derivative, or salt thereof, preferably comprising ALA, its derivative, or salt thereof, and an iron compound such as sodium ferrous citrate, iron sodium citrate and iron ammonium citrate; a food or food material for preventing/ameliorating an adult disease comprising the composition; and a method for using the composition for preparing an agent for preventing/ameliorating an adult disease.
BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
Use of PHY906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.
Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism
The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.
Heterocyclic compound
- Kazuaki Takami ,
- Masaki Seto ,
- Shinobu Sasaki ,
- Haruhi Ando ,
- Masaki Ogino ,
- Tomoko Ohashi ,
- Toshihiro Imaeda ,
- Ikuo Fujimori ,
- Yasuhiro Tsukimi ,
- Masami YAMADA ,
- Kenichiro Shimokawa ,
- Takeshi Wakabayashi ,
- Masataka MURAKAMI ,
- Makoto FUSHIMI ,
- Tomohiro Okawa ,
- Jinichi Yonemori ,
- Tomohiro Ohashi ,
- Hideo Suzuki ,
- Hironobu Maezaki ,
- Ayumu Sato ,
- Yasutomi Asano ,
- Steve SWANN
The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): ##STR00001##
wherein each symbol is as described in the specification, or a salt thereof.
Heterocyclic compound
- Kazuaki Takami ,
- Masaki Seto ,
- Shinobu Sasaki ,
- Haruhi Ando ,
- Masaki Ogino ,
- Tomoko Ohashi ,
- Toshihiro Imaeda ,
- Ikuo Fujimori ,
- Yasuhiro Tsukimi ,
- Masami YAMADA ,
- Kenichiro Shimokawa ,
- Takeshi Wakabayashi ,
- Masataka MURAKAMI ,
- Makoto FUSHIMI ,
- Tomohiro Okawa ,
- Jinichi Yonemori ,
- Tomohiro Ohashi ,
- Hideo Suzuki ,
- Hironobu Maezaki ,
- Ayumu Sato ,
- Yasutomi Asano ,
- Steve SWANN
The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): ##STR00001##
wherein each symbol is as described in the specification, or a salt thereof.
Composition and method for improving quantity of tear fluid, composition, treating constipation and improving skin quality
The present invention relates to a composition and method for improving the quantity of tear fluid, a composition and method for treating constipation, and a composition and method for improving skin quality. By utilizing an extract of Black ginger (Kaempferia parviflora)), the quantity of tear fluid, constipation, and skin quality are improved.
Composition and method for improving quantity of tear fluid, composition, treating constipation and improving skin quality
The present invention relates to a composition and method for improving the quantity of tear fluid, a composition and method for treating constipation, and a composition and method for improving skin quality. By utilizing an extract of Black ginger (Kaempferia parviflora)), the quantity of tear fluid, constipation, and skin quality are improved.